Newsfeeds - Spark Newswire

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

Today, 9:40 PM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL

4 minute read

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar

By Shanthi Rexaline

Today, 9:40 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ALKS

1 minute read

Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial

By Vandana Singh

Today, 9:40 PM

Sangamo Therapeutics Inc (NASDAQ: SGMO)

SGMO

3 minute read

Sangamo Therapeutics Offers Updated Prelim. Phase 1/2 Data On Its Fabry Disease Treatment: Was Generally Well Tolerated, 4 Patients In First 2 Dose Cohorts Showed Above Normal a-GAL A Activity

By Benzinga Newsdesk

Today, 9:40 PM

- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited above normal

SGMO

25 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 9:40 PM

During Friday's session, 445 companies made new 52-week lows.

AAOI

2 minute read

News

Sangamo Therapeutics Announces Sanofi Notified Co. Of Its Termination Of Collaboration Agreement, Effective June 28, 2022

By Benzinga Newsdesk

Today, 9:40 PM

On December 30, 2021, Bioverativ Therapeutics Inc. (f/k/a Biogen Idec Ma Inc.) (“Sanofi”) notified Sangamo Therapeutics, Inc. (“Sangamo”) of its termination for convenience, effective June 28,

SGMO

2 minute read

Pfizer, Sangamo Announced Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy Presented at ASH 2021

By Charles Gross

Today, 9:40 PM

Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc.

PFE

2 minute read

Sangamo Therapeutics Announced Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease at ASH 2021; Said All Four Treated Patients Experienced Increases In Total Hemoglobin, Fetal…

By Charles Gross

Today, 9:40 PM

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease (SCD).

SGMO

5 minute read

81 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:40 PM

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday.

ALXO

1 minute read

Why Did Sangamo Stock Jump 20% Today?

By Vandana Singh

Today, 9:40 PM

Sangamo Therapeutics Inc (NASDAQ:SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy…

SGMO